For research purposes only — not for human consumption — 18+ only

Retatrutide 30mg

$200.00

Research-grade Retatrutide 30mg vial. Triple agonist activity across GLP-1 GIP and glucagon receptors.

SKU: RT30 Category:

Reviews

There are no reviews yet.

Be the first to review “Retatrutide 30mg”

Your email address will not be published. Required fields are marked *

Retatrutide 30mg — the highest-dose vial of LY3437943 for comprehensive research programmes. This vial provides sufficient compound for multi-arm dose-response studies or extended animal model experiments using Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist. Phase II data showing 24.2% weight reduction at 48 weeks positions retatrutide as the most effective metabolic peptide compound currently in clinical development.

Molecular Data

Molecular Formula: C187H291N45O57 | Molecular Weight: 4130.6 g/mol | CAS Number: 2381606-29-3

Triple Receptor Mechanism

Acts simultaneously on GLP-1, GIP (at 8.9× endogenous potency), and glucagon receptors. The triple mechanism produces synergistic effects on appetite suppression, insulin sensitivity, and energy expenditure through three independent pathways — superior to single or dual agonist approaches.

Clinical Evidence

Phase II obesity trial: 17.5% mean weight loss at 24 weeks, 24.2% at 48 weeks at 12mg weekly dosing. Significant secondary improvements in lipid profiles, glycaemic control, blood pressure, and hepatic steatosis. Phase III TRIUMPH trials ongoing.

High-Volume Research

The 30mg vial is suited to comprehensive research programmes requiring larger quantities, including full dose-response curves from low to high dose, parallel treatment arms, or multi-tissue pharmacodynamic studies.

Future Research

Phase III TRIUMPH trials ongoing. Research extends to type 2 diabetes, MASLD, cardiovascular risk, and renal disease models.

Scroll to Top